secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2024-04-24T23:59:59+00:00
Accession:  0000950170-24-047560
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon reports 50% confirmed ORR with ACR-368 in OncoSignature-positive gynecological cancers; cash ~$234M
--------------------------------------------------------------------------------

- Phase 2b: 50% confirmed ORR in OncoSignature-positive ovarian/endometrial (10 pts), 0% ORR in negative (16), p=0.0038.
- Median duration of response not yet reached; all responders remain on treatment.
- ACR-2316 dual WEE1/PKMYT1 inhibitor IND filing accelerated to Q3 2024; clinical trial expected Q4 2024.
- Preliminary cash $110M at March 31; pro forma $234M after private placement, funding into H2 2026.
- Initial prospective validation of AP3 platform ability to predict ACR-368 responders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000095017024047560/0000950170-24-047560-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000095017024047560/acrv-20240424.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-047560

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer